Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Nilotinib-Induced Elephantine Psoriasis in a Patient With Chronic Myeloid Leukemia: A Rare Case Report and Literature Review Publisher



Sadatmadani SF1 ; Malakoutikhah Z2 ; Mohaghegh F3 ; Peikar M4 ; Saboktakin M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Skin Disease and Leishmaniasis Research Center, Department of Dermatology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Hematology and Oncology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Current Therapeutic Research - Clinical and Experimental Published:2022


Abstract

Tyrosine kinase inhibitors are anticancer drugs that disrupt signal transduction pathways in protein kinases by different mechanisms. This group of pharmacologic agents has significantly improved the outcome of patients with chronic myeloid leukemia. However, their effect is not limited to cancer cells, and various complications, particularly cutaneous reactions, have been reported. We report a very rare case of a 35-year-old female with a history of chronic myeloid leukemia who presented with elephantine psoriasis after the treatment with nilotinib. Conclusions: This case highlights a critical side effect of tyrosine kinase inhibitors. Awareness of this subject can be useful for better management of similar patients. © 2022 The Authors
Related Docs
1. Antidepressants and the Risk of Psoriasis Induction: A Case-Control Study, Advanced Biomedical Research (2023)
2. Jak Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? a Systematic Review of the Published Literature, Cancers (2024)
Experts (# of related papers)
Fariba Iraji (1)